查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1193118

抗球虫药市场：按药物类别（离子载体、合成药物）、药物作用（静态球虫、杀球虫）、动物类型（家禽、牛等）：全球机会分析和行业预测，2021-2031 年

Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 220 Pages | 商品交期: 2-3个工作天内

价格

2021 年全球抗球虫药市场价值 1.713 亿美元，预计 2022 年至 2031 年復合年增长率为 4.2%，2031 年达到 2.578 亿美元。

球虫病是家禽中最常见的疾病之一，由艾美球虫属的原生动物寄生虫引起。 这些寄生虫是强制性细胞内寄生虫，具有復杂的生命週期，包括有性和无性阶段。 这些寄生虫生活在肠道中，易患其他疾病（坏死性肠炎），并降低该器官吸收营养的能力。 该病通过昆虫和野鸟等机械媒介传播。 然而，在野生鸟类中，卵（卵囊）是机械运输的，但这些寄生虫是宿主特异性的，因此野生鸟类不能作为生物宿主。 因此，可以藉助抗球虫药物来控制疾病。 由于肉鸡的生命週期较短，可采用球虫等杀虫剂彻底消灭肠道内的艾美球虫。

抗球虫药物市场的增长是由先进抗球虫药物的不断发展推动的，政府加大力度提高对球虫病及其治疗的认识。 此外，对肉类和牛奶等动物蛋白食品的高需求、抗球虫药物合同开发的增加以及製药和生物技术行业的发展也在推动市场增长。 然而，严格的政府法规限制在牲畜中使用抗球虫药物以及疫苗和草药等替代药物的使用预计会阻碍该市场的增长。 相反，提高对价格可承受的新产品的认识有望在市场上创造有利可图的机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • 分析 COVID-19 对市场的影响

第 4 章抗球虫药市场：按治疗类别分类

  • 概览
    • 市场规模和预测
  • 离子载体
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 合成药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章抗球虫药物市场：按效力

  • 概览
    • 市场规模和预测
  • 杀菌剂
    • 主要市场趋势、增长因素和机遇
    • 各地区的市场规模和预测
    • 市场份额分析：按国家/地区分类
  • 杀菌剂
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章抗球虫药市场：按动物类型分类

  • 概览
    • 市场规模和预测
  • 家禽
    • 主要市场趋势、增长因素和机遇
    • 各地区的市场规模和预测
    • 市场份额分析：按国家/地区分类
  • 牛肉
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 其他
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章抗球虫药市场：按地区分类

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按药物类别
    • 北美市场规模和预测：按毒品行动
    • 北美市场规模和预测：按动物类型
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按药物类别
    • 欧洲市场规模和预测：按毒品行动
    • 欧洲市场规模和预测：按动物类型
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机会
    • 按药物类别划分的亚太市场规模和预测
    • 亚太市场规模和预测：按药物作用
    • 亚太地区市场规模和按动物类型预测
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 澳大利亚
      • 印度
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按药物类别
    • LAMEA 市场规模和预测：按药物作用
    • LAMEA 市场规模和预测：按动物类型
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地区

第八章公司情况

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 定位顶级公司，2021 年
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • boehringer ingelheim animal health-us
  • Ceva sante animale
  • Huvepharma EOOD
  • Merck & Co., Inc
  • Venkateshwara hatcheries Private Limited
  • Dosh Pharmaceuticals
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc
  • Bayer AG
Product Code: A14844

The global anticoccidial drugs market was valued at $171.3 million in 2021, and is projected to reach $257.8 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.

Coccidiosis is one of the most common diseases in the poultry population is caused by protozoan parasites of the genus Eimeria. These are obligated intracellular parasites with complex life cycles including sexual and asexual stages. These parasites affect the intestine making it prone to other diseases (necrotic enteritis) and reducing the ability of this organ to absorb nutrients. This disease is transmitted or spread by mechanical carriers such as insects and wild birds. However, the Eimeria eggs (oocysts) can be mechanically transported by wild birds, these parasites are host-specific and thus wild birds do not serve as a biological reservoir. Hence, this disease can be controlled by the help of anticoccidial drugs. The short life cycle of a broiler eliminates Eimeria completely from the gut by using the drugs like coccidicides that kill the parasites.

The growth of the anticoccidial drugs market is driven by the increase in development of advanced anticoccidial drugs, increase in the government initiatives for the awareness about the coccidiosis and its medications. Moreover, the high demand of animal protein food such as meat, milk, and others, increase in the outsourcing of the development of the anticoccidial drugs, and the development in the pharmaceutical and biotechnology industries also helps in the growth of the market. However, a stringent government regulations that restricts the usage of anticoccidial drugs in livestock and the use of alternative medicines such as vaccines and herbal medicines to treat coccidiosis are expected to hinder the growth of this market. Conversely, the rise in awareness about the new products available at affordable rates is expected to create lucrative opportunities for the market.

The global anticoccidial drugs market is segmented based on drug class, drug action, animal type, and region. On the basis of drug class, the market is bifurcated into ionophore and synthetic drugs. On the basis of drug action, the market is classified into coccidiostatic and coccidiocidal. On the basis of animal type, the market is classified into poultry, cattle and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key market players operating in this market include Bayer AG, Boehringer Ingelheim International GmbH, Ceva sante animale, Dosh Pharmaceuticals Private Limited, Huvepharma EOOD, Merck & Co., Inc., Venkateshwara hatcheries Private Limited, Vetoquinol SA, Virbac SA, Zoetis Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the anticoccidial drugs market analysis from 2021 to 2031 to identify the prevailing anticoccidial drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the anticoccidial drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global anticoccidial drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Ionophore
  • Synthetic Drugs

By Drug Action

  • Coccidiostatic
  • Coccidiocidal

By Animal Type

  • Poultry
  • Cattle
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • boehringer ingelheim animal health - us
    • Ceva sante animale
    • Huvepharma EOOD
    • Merck & Co., Inc
    • Venkateshwara hatcheries Private Limited
    • Dosh Pharmaceuticals
    • Vetoquinol SA
    • Virbac SA
    • Zoetis Inc
    • Bayer AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Ionophore
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Synthetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Coccidiostatic
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Coccidiocidal
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Poultry
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Cattle
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class
    • 7.2.3 North America Market size and forecast, by Drug Action
    • 7.2.4 North America Market size and forecast, by Animal Type
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Drug Class
      • 7.2.5.1.3 Market size and forecast, by Drug Action
      • 7.2.5.1.4 Market size and forecast, by Animal Type
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Drug Class
      • 7.2.5.2.3 Market size and forecast, by Drug Action
      • 7.2.5.2.4 Market size and forecast, by Animal Type
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Drug Class
      • 7.2.5.3.3 Market size and forecast, by Drug Action
      • 7.2.5.3.4 Market size and forecast, by Animal Type
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class
    • 7.3.3 Europe Market size and forecast, by Drug Action
    • 7.3.4 Europe Market size and forecast, by Animal Type
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Drug Class
      • 7.3.5.1.3 Market size and forecast, by Drug Action
      • 7.3.5.1.4 Market size and forecast, by Animal Type
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Drug Class
      • 7.3.5.2.3 Market size and forecast, by Drug Action
      • 7.3.5.2.4 Market size and forecast, by Animal Type
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Drug Class
      • 7.3.5.3.3 Market size and forecast, by Drug Action
      • 7.3.5.3.4 Market size and forecast, by Animal Type
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Drug Class
      • 7.3.5.4.3 Market size and forecast, by Drug Action
      • 7.3.5.4.4 Market size and forecast, by Animal Type
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Drug Class
      • 7.3.5.5.3 Market size and forecast, by Drug Action
      • 7.3.5.5.4 Market size and forecast, by Animal Type
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Drug Class
      • 7.3.5.6.3 Market size and forecast, by Drug Action
      • 7.3.5.6.4 Market size and forecast, by Animal Type
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Action
    • 7.4.4 Asia-Pacific Market size and forecast, by Animal Type
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Drug Class
      • 7.4.5.1.3 Market size and forecast, by Drug Action
      • 7.4.5.1.4 Market size and forecast, by Animal Type
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Drug Class
      • 7.4.5.2.3 Market size and forecast, by Drug Action
      • 7.4.5.2.4 Market size and forecast, by Animal Type
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Drug Class
      • 7.4.5.3.3 Market size and forecast, by Drug Action
      • 7.4.5.3.4 Market size and forecast, by Animal Type
      • 7.4.5.4 India
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Drug Class
      • 7.4.5.4.3 Market size and forecast, by Drug Action
      • 7.4.5.4.4 Market size and forecast, by Animal Type
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Drug Class
      • 7.4.5.5.3 Market size and forecast, by Drug Action
      • 7.4.5.5.4 Market size and forecast, by Animal Type
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Drug Class
      • 7.4.5.6.3 Market size and forecast, by Drug Action
      • 7.4.5.6.4 Market size and forecast, by Animal Type
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class
    • 7.5.3 LAMEA Market size and forecast, by Drug Action
    • 7.5.4 LAMEA Market size and forecast, by Animal Type
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Drug Class
      • 7.5.5.1.3 Market size and forecast, by Drug Action
      • 7.5.5.1.4 Market size and forecast, by Animal Type
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Drug Class
      • 7.5.5.2.3 Market size and forecast, by Drug Action
      • 7.5.5.2.4 Market size and forecast, by Animal Type
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Drug Class
      • 7.5.5.3.3 Market size and forecast, by Drug Action
      • 7.5.5.3.4 Market size and forecast, by Animal Type
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Drug Class
      • 7.5.5.4.3 Market size and forecast, by Drug Action
      • 7.5.5.4.4 Market size and forecast, by Animal Type

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Top player positioning, 2021
  • 8.5. Competitive Dashboard
  • 8.6. Competitive Heatmap
  • 8.7. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 boehringer ingelheim animal health - us
    • 9.1.1 Company overview
    • 9.1.2 Key Executives
    • 9.1.3 Company snapshot
    • 9.1.4 Operating business segments
    • 9.1.5 Product portfolio
    • 9.1.6 Business performance
    • 9.1.7 Key strategic moves and developments
  • 9.2 Ceva sante animale
    • 9.2.1 Company overview
    • 9.2.2 Key Executives
    • 9.2.3 Company snapshot
    • 9.2.4 Operating business segments
    • 9.2.5 Product portfolio
    • 9.2.6 Business performance
    • 9.2.7 Key strategic moves and developments
  • 9.3 Huvepharma EOOD
    • 9.3.1 Company overview
    • 9.3.2 Key Executives
    • 9.3.3 Company snapshot
    • 9.3.4 Operating business segments
    • 9.3.5 Product portfolio
    • 9.3.6 Business performance
    • 9.3.7 Key strategic moves and developments
  • 9.4 Merck & Co., Inc
    • 9.4.1 Company overview
    • 9.4.2 Key Executives
    • 9.4.3 Company snapshot
    • 9.4.4 Operating business segments
    • 9.4.5 Product portfolio
    • 9.4.6 Business performance
    • 9.4.7 Key strategic moves and developments
  • 9.5 Venkateshwara hatcheries Private Limited
    • 9.5.1 Company overview
    • 9.5.2 Key Executives
    • 9.5.3 Company snapshot
    • 9.5.4 Operating business segments
    • 9.5.5 Product portfolio
    • 9.5.6 Business performance
    • 9.5.7 Key strategic moves and developments
  • 9.6 Dosh Pharmaceuticals
    • 9.6.1 Company overview
    • 9.6.2 Key Executives
    • 9.6.3 Company snapshot
    • 9.6.4 Operating business segments
    • 9.6.5 Product portfolio
    • 9.6.6 Business performance
    • 9.6.7 Key strategic moves and developments
  • 9.7 Vetoquinol SA
    • 9.7.1 Company overview
    • 9.7.2 Key Executives
    • 9.7.3 Company snapshot
    • 9.7.4 Operating business segments
    • 9.7.5 Product portfolio
    • 9.7.6 Business performance
    • 9.7.7 Key strategic moves and developments
  • 9.8 Virbac SA
    • 9.8.1 Company overview
    • 9.8.2 Key Executives
    • 9.8.3 Company snapshot
    • 9.8.4 Operating business segments
    • 9.8.5 Product portfolio
    • 9.8.6 Business performance
    • 9.8.7 Key strategic moves and developments
  • 9.9 Zoetis Inc
    • 9.9.1 Company overview
    • 9.9.2 Key Executives
    • 9.9.3 Company snapshot
    • 9.9.4 Operating business segments
    • 9.9.5 Product portfolio
    • 9.9.6 Business performance
    • 9.9.7 Key strategic moves and developments
  • 9.10 Bayer AG
    • 9.10.1 Company overview
    • 9.10.2 Key Executives
    • 9.10.3 Company snapshot
    • 9.10.4 Operating business segments
    • 9.10.5 Product portfolio
    • 9.10.6 Business performance
    • 9.10.7 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. ANTICOCCIDIAL DRUGS MARKET FOR IONOPHORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. ANTICOCCIDIAL DRUGS MARKET FOR SYNTHETIC DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOSTATIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOCIDAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. ANTICOCCIDIAL DRUGS MARKET FOR POULTRY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. ANTICOCCIDIAL DRUGS MARKET FOR CATTLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. ANTICOCCIDIAL DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. ANTICOCCIDIAL DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY EXECUTIVES
  • TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: COMPANY SNAPSHOT
  • TABLE 87.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: OPERATING SEGMENTS
  • TABLE 88.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: PRODUCT PORTFOLIO
  • TABLE 89.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: NET SALES
  • TABLE 90.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY STRATERGIES
  • TABLE 92.CEVA SANTE ANIMALE: KEY EXECUTIVES
  • TABLE 92.CEVA SANTE ANIMALE: COMPANY SNAPSHOT
  • TABLE 93.CEVA SANTE ANIMALE: OPERATING SEGMENTS
  • TABLE 94.CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
  • TABLE 95.CEVA SANTE ANIMALE: NET SALES
  • TABLE 96.CEVA SANTE ANIMALE: KEY STRATERGIES
  • TABLE 98.HUVEPHARMA EOOD: KEY EXECUTIVES
  • TABLE 98.HUVEPHARMA EOOD: COMPANY SNAPSHOT
  • TABLE 99.HUVEPHARMA EOOD: OPERATING SEGMENTS
  • TABLE 100.HUVEPHARMA EOOD: PRODUCT PORTFOLIO
  • TABLE 101.HUVEPHARMA EOOD: NET SALES
  • TABLE 102.HUVEPHARMA EOOD: KEY STRATERGIES
  • TABLE 104.MERCK & CO., INC: KEY EXECUTIVES
  • TABLE 104.MERCK & CO., INC: COMPANY SNAPSHOT
  • TABLE 105.MERCK & CO., INC: OPERATING SEGMENTS
  • TABLE 106.MERCK & CO., INC: PRODUCT PORTFOLIO
  • TABLE 107.MERCK & CO., INC: NET SALES
  • TABLE 108.MERCK & CO., INC: KEY STRATERGIES
  • TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY EXECUTIVES
  • TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: COMPANY SNAPSHOT
  • TABLE 111.VENKATESHWARA HATCHERIES PRIVATE LIMITED: OPERATING SEGMENTS
  • TABLE 112.VENKATESHWARA HATCHERIES PRIVATE LIMITED: PRODUCT PORTFOLIO
  • TABLE 113.VENKATESHWARA HATCHERIES PRIVATE LIMITED: NET SALES
  • TABLE 114.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY STRATERGIES
  • TABLE 116.DOSH PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 116.DOSH PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 117.DOSH PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 118.DOSH PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 119.DOSH PHARMACEUTICALS: NET SALES
  • TABLE 120.DOSH PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 122.VETOQUINOL SA: KEY EXECUTIVES
  • TABLE 122.VETOQUINOL SA: COMPANY SNAPSHOT
  • TABLE 123.VETOQUINOL SA: OPERATING SEGMENTS
  • TABLE 124.VETOQUINOL SA: PRODUCT PORTFOLIO
  • TABLE 125.VETOQUINOL SA: NET SALES
  • TABLE 126.VETOQUINOL SA: KEY STRATERGIES
  • TABLE 128.VIRBAC SA: KEY EXECUTIVES
  • TABLE 128.VIRBAC SA: COMPANY SNAPSHOT
  • TABLE 129.VIRBAC SA: OPERATING SEGMENTS
  • TABLE 130.VIRBAC SA: PRODUCT PORTFOLIO
  • TABLE 131.VIRBAC SA: NET SALES
  • TABLE 132.VIRBAC SA: KEY STRATERGIES
  • TABLE 134.ZOETIS INC: KEY EXECUTIVES
  • TABLE 134.ZOETIS INC: COMPANY SNAPSHOT
  • TABLE 135.ZOETIS INC: OPERATING SEGMENTS
  • TABLE 136.ZOETIS INC: PRODUCT PORTFOLIO
  • TABLE 137.ZOETIS INC: NET SALES
  • TABLE 138.ZOETIS INC: KEY STRATERGIES
  • TABLE 140.BAYER AG: KEY EXECUTIVES
  • TABLE 140.BAYER AG: COMPANY SNAPSHOT
  • TABLE 141.BAYER AG: OPERATING SEGMENTS
  • TABLE 142.BAYER AG: PRODUCT PORTFOLIO
  • TABLE 143.BAYER AG: NET SALES
  • TABLE 144.BAYER AG: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1. SEGMENTATION OF ANTICOCCIDIAL DRUGS MARKET,2021-2031
  • FIGURE 2.ANTICOCCIDIAL DRUGS MARKET,2021-2031
  • FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 4.PORTER FIVE-1
  • FIGURE 5.PORTER FIVE-2
  • FIGURE 6.PORTER FIVE-3
  • FIGURE 7.PORTER FIVE-4
  • FIGURE 8.PORTER FIVE-5
  • FIGURE 9.ANTICOCCIDIAL DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10.ANTICOCCIDIAL DRUGS MARKET,BY DRUG CLASS,2021(%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF IONOPHORE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF SYNTHETIC DRUGS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 13.ANTICOCCIDIAL DRUGS MARKET,BY DRUG ACTION,2021(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF COCCIDIOSTATIC ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COCCIDIOCIDAL ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 16.ANTICOCCIDIAL DRUGS MARKET,BY ANIMAL TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF POULTRY ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CATTLE ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTICOCCIDIAL DRUGS MARKET, 2021 AND 2031(%)
  • FIGURE 20.ANTICOCCIDIAL DRUGS MARKET BY REGION,2021
  • FIGURE 21.U.S. ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 22.CANADA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 23.MEXICO ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 24.GERMANY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 25.FRANCE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 26.UK ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 27.ITALY ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 28.SPAIN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 29.REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 30.JAPAN ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 31.CHINA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 32.AUSTRALIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 33.INDIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 34.SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 36.BRAZIL ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 37.SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET,2021-2031($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44.TOP PLAYER POSITIONING, 2021
  • FIGURE 45.COMPETITIVE DASHBOARD
  • FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 47.BOEHRINGER INGELHEIM ANIMAL HEALTH - US.: NET SALES ($MILLION)
  • FIGURE 48.CEVA SANTE ANIMALE.: NET SALES ($MILLION)
  • FIGURE 49.HUVEPHARMA EOOD.: NET SALES ($MILLION)
  • FIGURE 50.MERCK & CO., INC.: NET SALES ($MILLION)
  • FIGURE 51.VENKATESHWARA HATCHERIES PRIVATE LIMITED.: NET SALES ($MILLION)
  • FIGURE 52.DOSH PHARMACEUTICALS.: NET SALES ($MILLION)
  • FIGURE 53.VETOQUINOL SA.: NET SALES ($MILLION)
  • FIGURE 54.VIRBAC SA.: NET SALES ($MILLION)
  • FIGURE 55.ZOETIS INC.: NET SALES ($MILLION)
  • FIGURE 56.BAYER AG.: NET SALES ($MILLION)